Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)
Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%
Pfizer Finite-lived intangible assets by Quarter
Finite-lived intangible assets — Gross carrying amount ($M) ($M)
Pfizer Finite-lived intangible assets: $104,198M in Q2 2026, down 0.3% from a year earlier.
Latest, Q2 2026
104,198
Period ended Jun 28, 2026
Change on a year earlier
-0.3%
104,551 in Q2 2025
History
46 quarters
Since Q1 2015
Sources
45
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Goodwill & Other Intangible Assets Footnote.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Finite-lived intangible assets — Gross carrying amount ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 28, 2026 | 104,198 | -0.3% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 29, 2026 | 104,780 | +1.3% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 104,006 | +0.6% | Form 10-Q (filed 2026-08-04) ↗ |
| Q3 2025 | Sep 28, 2025 | 104,849 | +1.0% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 29, 2025 | 104,551 | +0.6% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2025 | Mar 30, 2025 | 103,401 | -0.6% | Form 10-Q (filed 2025-05-05) ↗ |
| Q4 2024 | Dec 31, 2024 | 103,397 | +0.4% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2024 | Sep 29, 2024 | 103,842 | +16.3% | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 103,959 | +16.3% | Form 10-Q (filed 2024-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 104,046 | +17.8% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 102,944 | +16.0% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2023 | Oct 1, 2023 | 89,290 | +17.4% | Form 10-Q (filed 2023-11-08) ↗ |
| Q2 2023 | Jul 2, 2023 | 89,376 | +17.1% | Form 10-Q (filed 2023-08-09) ↗ |
| Q1 2023 | Apr 2, 2023 | 88,315 | +15.5% | Form 10-Q (filed 2023-05-10) ↗ |
| Q4 2022 | Dec 31, 2022 | 88,763 | +16.0% | Form 10-K (filed 2024-02-22) ↗ |
| Q3 2022 | Oct 2, 2022 | 76,036 | -1.7% | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2022 | Jul 3, 2022 | 76,315 | -1.6% | Form 10-Q (filed 2022-08-10) ↗ |
| Q1 2022 | Apr 3, 2022 | 76,436 | -1.1% | Form 10-Q (filed 2022-05-11) ↗ |
| Q4 2021 | Dec 31, 2021 | 76,552 | +0.4% | Form 10-K (filed 2023-02-23) ↗ |
| Q3 2021 | Oct 3, 2021 | 77,350 | -17.1% | Form 10-Q (filed 2021-11-12) ↗ |
| Q2 2021 | Jul 4, 2021 | 77,582 | -16.7% | Form 10-Q (filed 2021-08-12) ↗ |
| Q1 2021 | Apr 4, 2021 | 77,284 | -15.3% | Form 10-Q (filed 2021-05-13) ↗ |
| Q4 2020 | Dec 31, 2020 | 76,255 | +1.6% | Form 10-K (filed 2022-02-24) ↗ |
| Q3 2020 | Sep 27, 2020 | 93,358 | -0.6% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2020 | Jun 28, 2020 | 93,176 | +1.4% | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2020 | Mar 29, 2020 | 91,221 | -0.6% | Form 10-Q (filed 2020-05-07) ↗ |
| Q4 2019 | Dec 31, 2019 | 75,058 | -18.2% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2019 | Sep 29, 2019 | 93,910 | -2.4% | Form 10-Q (filed 2019-11-07) ↗ |
| Q2 2019 | Jun 30, 2019 | 91,903 | -1.9% | Form 10-Q (filed 2019-08-08) ↗ |
| Q1 2019 | Mar 31, 2019 | 91,743 | -2.4% | Form 10-Q (filed 2019-05-09) ↗ |
| Q4 2018 | Dec 31, 2018 | 91,788 | -1.9% | Form 10-K (filed 2020-02-27) ↗ |
| Q3 2018 | Sep 30, 2018 | 96,187 | +2.7% | Form 10-Q (filed 2018-11-08) ↗ |
| Q2 2018 | Jul 1, 2018 | 93,665 | +0.2% | Form 10-Q (filed 2018-08-09) ↗ |
| Q1 2018 | Apr 1, 2018 | 93,996 | +1.1% | Form 10-Q (filed 2018-05-10) ↗ |
| Q4 2017 | Dec 31, 2017 | 93,595 | +7.1% | Form 10-K (filed 2019-02-28) ↗ |
| Q3 2017 | Oct 1, 2017 | 93,650 | +6.6% | SEC Filing ↗ |
| Q2 2017 | Jul 2, 2017 | 93,520 | +15.1% | SEC Filing ↗ |
| Q1 2017 | Apr 2, 2017 | 92,994 | +14.1% | SEC Filing ↗ |
| Q4 2016 | Dec 31, 2016 | 87,351 | +7.6% | Form 10-K (filed 2018-02-22) ↗ |
| Q3 2016 | Oct 2, 2016 | 87,854 | +5.6% | SEC Filing ↗ |
| Q2 2016 | Jul 3, 2016 | 81,242 | +11.0% | SEC Filing ↗ |
| Q1 2016 | Apr 3, 2016 | 81,505 | +11.3% | SEC Filing ↗ |
| Q4 2015 | Dec 31, 2015 | 81,205 | – | Form 10-K (filed 2017-02-23) ↗ |
| Q3 2015 | Sep 27, 2015 | 83,225 | – | SEC Filing ↗ |
| Q2 2015 | Jun 28, 2015 | 73,186 | – | SEC Filing ↗ |
| Q1 2015 | Mar 29, 2015 | 73,219 | – | SEC Filing ↗ |
Cite this data
StockData. (2026). Pfizer Finite-lived intangible assets ($M), quarterly Q1 2015–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/intang-gross-tot
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.